Browse Pradaxa

Pradaxa is a leading brand in anticoagulation therapy, designed to reduce the risk of stroke and blood clots in patients with atrial fibrillation (AF) and venous thromboembolism (VTE). Its active ingredient, dabigatran, is a direct thrombin inhibitor that effectively prevents the formation of blood clots by inhibiting thrombin, a key enzyme in the clotting process. Pradaxa is well-regarded for its efficacy, predictable dosing, and reduced need for routine monitoring compared to traditional anticoagulants. The brand’s commitment to patient care is supported by extensive clinical research and a strong safety profile, making Pradaxa a trusted choice for anticoagulation therapy. Boehringer Ingelheim’s focus on innovation and comprehensive support ensures that Pradaxa offers effective, convenient, and reliable management of clotting disorders, contributing to improved patient outcomes and quality of life.